Hints and tips:
Related Special Reports
...After the latter was bought by Swiss pharmaceutical group Roche in 2009, he rose through the ranks, becoming Genentech’s chief executive in 2017 and Roche’s head of pharma two years later....
...Companies including UK’s AstraZeneca and Swiss group Roche have recently acquired or licensed weight-loss drugs in an effort to enter a market that analysts expected would exceed $100bn by 2030....
...Swiss company Roche acquired obesity drug developer Carmot Therapeutics for $3.1bn last month, while AstraZeneca signed a $2bn licensing agreement with Eccogene, a Chinese maker of an oral obesity drug in...
...Miels said that the pharmaceutical company has since “rebuilt” its business in China....
...Dwindling sales related to Covid-19 and the strong Swiss franc in 2023 hit revenues at pharmaceutical company Roche, which said it would return to sales growth in 2024....
...That is not the case for pharmaceutical companies. Novo Nordisk and Eli Lilly are already striding ahead with anti-obesity treatments....
...Roche has agreed to buy anti-obesity drug developer Carmot Therapeutics for up to $3.1bn, as the Swiss pharmaceutical group joins the industry’s charge into the fast-growing market for weight loss treatments...
...That holds true for pharmaceutical companies which are looking a bit peaky. Roche, whose stock has fallen 27 per cent in the past 12 months, is a case in point....
...Teresa Graham, chief of Roche’s pharmaceutical division, said more patients suffered from diseases of the immune system than from cancer, and the current drugs did not serve them well....
...Pharmaceutical companies must replenish their drugs pipeline before exclusivity rights on top-selling products expire....
...The former Roche pharmaceuticals boss took on one of the most unenviable jobs in corporate Europe last June....
...Consider how Roche spent its cash. It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...While the drug being developed by Swiss pharmaceutical group Roche has been tested on only one type of bacteria, the way it works suggests it could be effective against other microbes — and encourage much-needed...
...A former Roche manager who joined the German group last year, Anderson said he acknowledged the appeal of a “pure play structure” of pharma, crop science and over-the-counter consumer drugs....
...Ubben disclosed a 0.83 per cent stake in Bayer a year ago, becoming a leading force behind the ousting of then chief executive Werner Baumann, who was replaced by Bill Anderson, a former Roche manager....
...One of my first jobs at the Financial Times was writing about pharmaceuticals....
...Shares in Roche increased 5.1 per cent to SFr265.95....
...Anderson, a former executive at Swiss rival Roche, said he was seeking to “rebase expectations”....
...Chief executive Bill Anderson, who joined last year after heading the pharma unit of Swiss rival Roche, said the decision “was not taken lightly” and had “considered investor input.”...
...Swiss pharmaceutical company Roche is conducting phase 1 clinical trials on an antibiotic that successfully targeted a Gram-negative bacterium known as carbapenem-resistant Acinetobacter baumannii, or Crab...
...High demand for weight-loss drugs has helped Novo Nordisk become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s largest pharmaceutical company...
...Roche and AstraZeneca have acquired or signed licensing deals with biotechs developing weight-loss treatments in the past year....
...Roche recently agreed to buy the company for up to $3bn. The plan is to combine its drugs with ones in the Swiss company’s pipeline, with a view to preserving muscle mass....
...Roche and AstraZeneca have already struck deals to buy or license early stage weight-loss drugs....
...Novartis trades on a forward price/earnings ratio of 13.6, higher than some European peers such as Roche and Sanofi....
International Edition